Leap Therapeutics Inc (NASDAQ:LPTX) shares, rose in value on Wednesday, June 18, with the stock price up by 3.66% to the previous day’s close as strong demand from buyers drove the stock to $0.39.
Actively observing the price movement in the last trading, the stock closed the session at $0.38, falling within a range of $0.3803 and $0.41. The value of beta (5-year monthly) was -0.223. Referring to stock’s 52-week performance, its high was $4.79, and the low was $0.22. On the whole, LPTX has fluctuated by -5.88% over the past month.
With the market capitalization of Leap Therapeutics Inc currently standing at about $16.18 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LPTX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LPTX currently trading nearly 0.14% and 2.89% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.27, while the 7-day volatility ratio is showing 3.76% which for the 30-day chart, stands at 4.01%. Furthermore, Leap Therapeutics Inc (LPTX)’s beta value is -0.22, and its average true range (ATR) is 0.04.
A comparison of Leap Therapeutics Inc (LPTX) with its peers suggests the former has fared considerably weaker in the market. LPTX showed an intraday change of 3.66% in last session, and over the past year, it shrunk by -81.50%%.
Data on historical trading for Leap Therapeutics Inc (NASDAQ:LPTX) indicates that the trading volumes over the past 10 days have averaged 0.31 and over the past 3 months, they’ve averaged 2.12 million. According to company’s latest data on outstanding shares, there are 41.44 million shares outstanding.
Nearly 25.81% of Leap Therapeutics Inc’s shares belong to company insiders and institutional investors own 21.56% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.54 million shares as on 2025-05-30, resulting in a short ratio of 4.59. According to the data, the short interest in Leap Therapeutics Inc (LPTX) stood at 437.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 2.21 million. The stock has fallen by -86.42% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LPTX stock heading into the next quarter.
